BioLineRx Announces Publication of Pre-clinical Results Demonstrating Efficacy of BL-7010, an Oral Treatment for Celiac Disease and Gluten Sensitivity

Just last week BioLineRx, a biopharmaceutical development company announced successful pre-clinical testing of a potentially revolutionary treatment for celiac disease. This new treatment may help celiac disease patients reduce their gluten toxins to create an overall healthy body for all celiac disease patients.
Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body). The research was published in the February edition of Gastroenterology.
The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, thereby decreasing its









Among the most notable athletes making the gluten free switch are Raul Ibanez of the Philadelphia Phillies, Cedric Benson of the Cincinnati Bengals, and tennis player Novak Djokovic, the 2011 winner of Wimbledon who went on an unprecedented 43-match win streak. Most significant about their decision to go gluten free is the marked improvement in all three athletes after the switch.
